A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)
Sarit Assouline(Jewish General Hospital), Seung‐Tae Lee(University Health System), Rosemary Harrup(University of Tasmania), Katharine L. Lewis(Linear Clinical Research), Jutta Deckert(Harvard University), Debra L. Wood, Jenny Thirlway, Paul I. Nadler, Robert J. Lutz(e-Therapeutics (United Kingdom)), David Browning
Cited by 2
Related Papers
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
|The Lancet Oncology|2022|429
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
|Blood|2019|369
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
|Clinical Cancer Research|2015|355